Quest Diagnostics stock falls 5.2 percent before the bell
Published on 09/22/2026 at 06:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics stock closed at USD 244.00 on the NYSE on September 21, 2026, down 0.6 percent. The shares had reached a fresh 52-week high of USD 248.84 intraday before falling 5.2 percent after hours to USD 232.12 after proposed Medicare laboratory fee cuts were released.
September 21, 2026 in numbers
Quest Diagnostics Incorporated (ISIN US74834L1008, NYSE: DGX) traded between USD 243.70 and USD 248.84 during the NYSE session, according to the session data reported by Investing.com.
After hours, the stock fell 5.2 percent to USD 232.12. The move contrasted with a nearly flat S&P 500, while the regulatory proposal indicated laboratory fee reductions of up to 15 percent from January 1, 2027.
Medicare rates weigh today
As Investing.com reported on September 21, 2026, the Centers for Medicare and Medicaid Services released preliminary reimbursement proposals that could reduce laboratory payments by up to 15 percent beginning January 1, 2027. The proposal affects the broader laboratory sector, including Quest Diagnostics and Labcorp, and formal comments are due within approximately 30 days.
